Duan J, et al. - Via performing this meta-analysis, researchers sought to determine the effectiveness of HCQ in improving the maternal and fetal outcomes in pregnancies with SLE. Searching PubMed, MEDLINE, EMBASE, and the Cochrane database, they identified nine studies involving 1,132 pregnancies for inclusion in the study (3 case controls, 2 prospective cohorts, 4 retrospective cohorts). In these studies, the maternal and/or fetal outcomes were compared between pregnant patients with SLE who were administered HCQ during pregnancy (HCQ+ group) and those who were not administered HCQ (HCQ− group). Per outcomes, the risk of preeclampsia, pregnancy hypertension and prematurity could be reduced in SLE patients by providing HCQ treatment during pregnancy. Evidence gained were of high certainty, however, the majority of the studies included are retrospective studies and not randomized controlled trials. Hence, HCQ use should be promoted in the multidisciplinary management of pregnant patients with SLE, irrespective of disease activity or severity.